Status:
RECRUITING
Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome.
Lead Sponsor:
Lund University Hospital
Conditions:
Mycosis Fungoides
Sezary Syndrome
Eligibility:
All Genders
18-100 years
Brief Summary
A translational study for identification of prognostic and treatment-predictive biomarkers in Mycosis fungoides and Sézary syndrome.
Eligibility Criteria
Inclusion
- Age 18-100 years
- Histologically confirmed (according to the World Health Organization (WHO)/EORTC classification) MF/SS stages I-IV
- WHO performance status 0 -3
- Absence of psychiatric illness or condition which could interfere with the subjects' ability to understand the requirements of the study.
- Written informed consent according to International Conference on Harmonization (ICH)/(Good Clinical Practice (GCP), and Swedish regulations
- No minimum or maximum required routine laboratory data
Exclusion
- Not applicable. No exclusion criteria are specified.
Key Trial Info
Start Date :
April 2 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2027
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04904146
Start Date
April 2 2021
End Date
April 1 2027
Last Update
March 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lund University Hospital
Lund, Sweden, SE-221 85